Delayed administration of suramin attenuates the progression of renal fibrosis in obstructive nephropathy

Journal of Pharmacology and Experimental Therapeutics

Volumn 338, Issue 3, 2011, Pages 758-766

  Liu, Na ^a   Tolbert, Evelyn ^b   Ponnusamy, Murugavel ^b   Yan, Haidong ^a   Zhuang, Shougang ^a,b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRONECTIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SMAD3 PROTEIN; STAT3 PROTEIN; SURAMIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; FIBROBLAST CULTURE; FIBROGENESIS; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY INTERSTITIUM; MALE; MOUSE; NONHUMAN; OBSTRUCTIVE NEPHROPATHY; ONSET AGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; THERAPY DELAY; URETER OBSTRUCTION;

ACTINS; ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; COLLAGEN TYPE I; DISEASE PROGRESSION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLASTS; FIBRONECTINS; FIBROSIS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; NEPHRITIS, INTERSTITIAL; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SMAD3 PROTEIN; SURAMIN; URETERAL OBSTRUCTION;

EID: 80052164170     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.181727     Document Type: Article

References (35)

1. Abdiu A, Larsson SE, Wasteson A, and Walz TM (1999) Suramin blocks growth-stimulatory effects of platelet-derived growth factor on malignant fibrous histiocytomas in vitro. Cancer Lett 146:189-194. (Pubitemid 29492889)
2. Bonner JC (2004) Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 15:255-273.
3. Boor P, Sebeková K, Ostendorf T, and Floege J (2007) Treatment targets in renal fibrosis. Nephrol Dial Transplant 22:3391-3407. (Pubitemid 350212482)
4. Chan YS, Li Y, Foster W, Horaguchi T, Somogyi G, Fu FH, and Huard J (2003) Antifibrotic effects of suramin in injured skeletal muscle after laceration. J Appl Physiol 95:771-780.
5. Coffey RJ Jr, Leof EB, Shipley GD, and Moses HL (1987) Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. J Cell Physiol 132:143-148. (Pubitemid 17105335)
6. Debelle FD, Nortier JL, Husson CP, De Prez EG, Vienne AR, Rombaut K, Salmon IJ, Deschodt-Lanckman MM, and Vanherweghem JL (2004) The renin-angiotensin system blockade does not prevent renal interstitial fibrosis induced by aristolochic acids. Kidney Int 66:1815-1825. (Pubitemid 41094305)
7. Fujiuchi S, Ohsaki Y, and Kikuchi K (1997) Suramin inhibits the growth of non-small-cell lung cancer cells that express the epidermal growth factor receptor. Oncology 54:134-140. (Pubitemid 27101761)
8. Gonçalves RG, Gabrich L, Rosário A Jr, Takiya CM, Ferreira ML, Chiarini LB, Persechini PM, Coutinho-Silva R, and Leite M Jr (2006) The role of purinergic P2X7 receptors in the inflammation and fibrosis of unilateral ureteral obstruction in mice. Kidney Int 70:1599-1606. (Pubitemid 44606995)
9. Ivashkiv LB and Hu X (2004) Signaling by STATs. Arthritis Res Ther 6:159-168. (Pubitemid 39162378)
10. Kim EK and Choi EJ (2010) Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 1802:396-405.
11. Kloen P, Jennings CL, Gebhardt MC, Springfield DS, and Mankin HJ (1994) Suramin inhibits growth and transforming growth factor-β1 (TGF-β1) binding in osteosarcoma cell lines. Eur J Cancer 30A:678-682.
12. Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, Lee DC, Friedlander G, and Terzi F (2005) Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med 11:867-874. (Pubitemid 41161119)
13. Li C, Jiang X, Yang L, Liu X, Yue S, and Li L (2009) Involvement of sphingosine 1-phosphate (SIP)/S1P3 signaling in cholestasis-induced liver fibrosis. Am J Pathol 175:1464-1472.
14. Liu N, Tolbert E, Pang M, Ponnusamy M, Yan H, and Zhuang S (2011) Suramin inhibits renal fibrosis in chronic kidney disease. J Am Soc Nephrol 22:1064-1075.
15. Liu Y (2006) Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 69:213-217.
16. Lo HW, Hsu SC, Xia W, Cao X, Shih JY, Wei Y, Abbruzzese JL, Hortobagyi GN, and Hung MC (2007) Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res 67:9066-9076. (Pubitemid 47535891)
17. Locatelli F, Del Vecchio L, and Cavalli A (2009) Inhibition of the renin-angiotensin system in chronic kidney disease: a critical look to single and dual blockade. Nephron Clin Pract 113:c286-293.
18. Masaki T, Stambe C, Hill PA, Dowling J, Atkins RC, and Nikolic-Paterson DJ (2004) Activation of the extracellular-signal regulated protein kinase pathway in human glomerulopathies. J Am Soc Nephrol 15:1835-1843.
19. Morrow BD, Stewart IJ, Barnes EW, and Cotant CL (2010) Chronic kidney disease management in an academic internal medicine clinic. Clin Exp Nephrol 14:137-143.
20. Neilson EG (2006) Mechanisms of disease: fibroblasts - a new look at an old problem. Nat Clin Pract Nephrol 2:101-108.
21. Pang M, Kothapally J, Mao H, Tolbert E, Ponnusamy M, Chin YE, and Zhuang S (2009) Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol 297:F996-F1005.
22. Pang M, Ma L, Gong R, Tolbert E, Mao H, Ponnusamy M, Chin YE, Yan H, Dworkin LD, and Zhuang S (2010) A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney Int 78:257-268.
23. Qin H, Wang L, Feng T, Elson CO, Niyongere SA, Lee SJ, Reynolds SL, Weaver CT, Roarty K, Serra R, et al. (2009) TGF-β promotes Th17 cell development through inhibition of SOCS3. J Immunol 183:97-105.
24. Sekine S, Nitta K, Uchida K, Yumura W, and Nihei H (2003) Possible involvement of mitogen-activated protein kinase in the angiotensin II-induced fibronectin synthesis in renal interstitial fibroblasts. Arch Biochem Biophys 415:63-68. (Pubitemid 36687917)
25. Song CY, Kim BC, Hong HK, and Lee HS (2007) TGF-β type II receptor deficiency prevents renal injury via decrease in ERK activity in crescentic glomerulonephritis. Kidney Int 71:882-888. (Pubitemid 46663790)
26. Stein CA (1993) Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res 53:2239-2248.
27. Stein CA, LaRocca RV, Thomas R, McAtee N, and Myers CE (1989) Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol 7:499-508. (Pubitemid 19098145)
28. Suzuki H, Uchida K, Nitta K, and Nihei H (2004) Role of mitogen-activated protein kinase in the regulation of transforming growth factor-β-induced fibronectin accumulation in cultured renal interstitial fibroblasts. Clin Exp Nephrol 8:188-195. (Pubitemid 39421367)
29. Suzuki K, Wilkes MC, Garamszegi N, Edens M, and Leof EB (2007) Transforming growth factor β signaling via Ras in mesenchymal cells requires p21-activated kinase 2 for extracellular signal-regulated kinase-dependent transcriptional responses. Cancer Res 67:3673-3682. (Pubitemid 46762152)
30. Terzi F, Burtin M, Hekmati M, Federici P, Grimber G, Briand P, and Friedlander G (2000) Targeted expression of a dominant-negative EGF-R in the kidney reduces tubulo-interstitial lesions after renal injury. J Clin Invest 106:225-234. (Pubitemid 30483126)
31. Urasawa K, Kaneta S, Nakano N, Saito T, Sakai H, Takagi C, Takagi Y, Sugiki H, and Kitabatake A (2001) Vascular smooth muscle cell proliferation is effectively suppressed by the non-specific growth factor inhibitor suramin. Jpn Heart J 42:221-233. (Pubitemid 32377495)
32. Vignais ML, Sadowski HB, Watling D, Rogers NC, and Gilman M (1996) Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins. Mol Cell Biol 16:1759-1769. (Pubitemid 26095648)
33. Wang W, Koka V, and Lan HY (2005) Transforming growth factor-β and Smad signalling in kidney diseases. Nephrology 10:48-56. (Pubitemid 40349406)
34. Wynn TA (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 214:199-210.
35. Zumkeller W and Schofield PN (1995) Growth factors, cytokines and soluble forms of receptor molecules in cancer patients. Anticancer Res 15:343-348.